Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acetate approved for the management of heavy menstrual bleed...

Descripción completa

Detalles Bibliográficos
Autores principales: Winzenborg, Insa, Polepally, Akshanth R., Nader, Ahmed, Mostafa, Nael M., Noertersheuser, Peter, Ng, Juki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438813/
https://www.ncbi.nlm.nih.gov/pubmed/32621325
http://dx.doi.org/10.1002/psp4.12545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438813/
https://www.ncbi.nlm.nih.gov/pubmed/32621325
http://dx.doi.org/10.1002/psp4.12545

Ejemplares similares